SEC Form 4 · accession 0001144204-16-090407
Akari Therapeutics Plc · AKTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Robert M Shaw
Officer — General Counsel and Secretary
Period of report
Mar 23, 2016
Accepted (ET)
Mar 25, 2016 · 4:16 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001541157
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Options to Purchase Ordinary SharesF1 | $14.10 | Mar 23, 2016 | A | 1,800,000 | A | Mar 23, 2016 | Mar 23, 2026 | Ordinary Shares | 1,800,000 | 1,800,000 | D |
Explanation of responses
- F112.5% of the shares underlying the option will vest on a semi-annual basis over a four year period beginning on 3/23/2016.